Arme Construction Company

Industry Veteran Cuong Do Joins Seneca Therapeutics, Inc. Advisory Board

Retrieved on: 
Tuesday, May 31, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, STI, Wilms' tumor, Genome, Therapy, Trial of the century, Forward-looking statement, Technology, Neoplasm, Arme Construction Company, SVV, CEO, Pharmaceutical industry

Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers, announced today that Cuong Do, a longtime industry veteran has joined the Seneca Therapeutics Advisory Board.

Key Points: 
  • Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers, announced today that Cuong Do, a longtime industry veteran has joined the Seneca Therapeutics Advisory Board.
  • We are pleased that Cuong has agreed to serve on our Advisory Board, said James Hussey, CEO of Seneca Therapeutics.
  • His insights on the development of SVV Armed Constructs and the SVV Gene Library have been particularly helpful.
  • I am pleased to join the Seneca Advisory Board, said Mr. Do.

Seneca Therapeutics, Inc. Announces Novel SVV-001 Patient Screening Test For Patient Selection With SVV-001 Therapy

Retrieved on: 
Tuesday, September 14, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Cancer, Therapy, Senecavirus, Forward-looking statement, Arme Construction Company, Patient, Gene, Genome, Sarcoma, Laboratory, Founder, CLIA, CSO, Seneca, Intravenous therapy, Medical imaging, Pharmaceutical industry

The SVV-001 Patient Screening Test can be used on Formalin-Fixed-Paraffin-Embedded (FFPE) tumor blocks allowing for patient screening using previous biopsies.

Key Points: 
  • The SVV-001 Patient Screening Test can be used on Formalin-Fixed-Paraffin-Embedded (FFPE) tumor blocks allowing for patient screening using previous biopsies.
  • The SVV-001 Patient Screening Test can also be used to identify types of cancer patients that will benefit from SVV-001.
  • The selection of patients using the SVV-001 Patient Screening Test will be applicable whether the patient is treated with either the Intra-tumoral or Intravenous route of administration.
  • Seneca Therapeutics is also using the SVV-001 Patient Screening Test to identify relevant cancer patient populations that could benefit from SVV-001 therapy.